STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is exp ...

The transaction is subject to the satisfaction of customary closing conditions and is expected to close in H1 2026. Sobi plans to fund the upfront payment mainly through debt in the form of existing credit facilities and a new credit facility provided by Handelsbanken and Danske Bank. The acquisition is expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory. Barclays Bank PLC is acting as Sobi's financial advisor and McDermott, Will & Schulte is acting as legal advisor to S ...